{'fraction_non_alphanumeric': 0.03247863247863248, 'fraction_numerical': 0.0, 'mean_word_length': 5.813953488372093, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Ameliorative potential of D‐Ribose‐L‐Cysteine in male Wistar rats with metabolic syndrome

Metabolic Syndrome (MS) refers to cluster of cardiometabolic risk factors which include obesity, insulin resistance, dyslipidaemia, hyperglycaemia and hypertension. Although, oxidative stress is implicated in its aetiology, protocols in MS management have not included the use of antioxidants. D‐ribose‐L‐cysteine (DRLC) is a potent antioxidant which has been suggested to be useful in the management of dyslipidaemia. This study was designed to investigate the effects of DRLC in rats with MS.